期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 54, 期 4, 页码 531-545出版社
ELSEVIER
DOI: 10.1016/S0169-409X(02)00026-1
关键词
poly(ethylene glycol); monoclonal antibody; Fab'; single chain antibodies; antibody fragment; pharmacokinetics
The use of covalent attachment of poly(ethylene glycol) to various different proteins in order to modify their function has been reported over many years. One class of protein that this technology has more recently been applied to is antibodies and antibody fragments. PEG has been predominantly used to reduce the immunogenicity and increase the circulating half-lives of antibodies. It may also have a beneficial effect on the use of antibodies in certain clinical settings such as tumour targeting. This review describes previously reported experience with PEGylated antibodies and antibody fragments, and where these types of molecules may find clinical usefulness in the future. (C) 2002 Elsevier Science B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据